Targeting hypoxia-inducible factors with 32-134D safely and effectively treats diabetic eye disease in mice

Targeting hypoxia-inducible factors with 32-134D safely and effectively treats diabetic eye disease in mice

Many patients with diabetic eye disease respond inadequately to anti-VEGF therapies, implicating additional vasoactive mediators in its pathogenesis. We demonstrate that levels of angiogenic proteins regulated by HIF-1 and -2 remain elevated in the eyes of people with diabetes despite treatment with...

Full description

Bibliographic Details
Main Authors: Jing Zhang, Deepti Sharma, Aumreetam Dinabandhu, Jaron Sanchez, Brooks Applewhite, Kathleen Jee, Monika Deshpande, Miguel Flores-Bellver, Ming-Wen Hu, Chuanyu Guo, Shaima Salman, Yousang Hwang, Nicole M. Anders, Michelle A. Rudek, Jiang Qian, M. Valeria Canto-Soler, Gregg L. Semenza, Silvia Montaner, Akrit Sodhi
Format: Article
Language:English
Published: American Society for Clinical Investigation 2023-07-01
Series:The Journal of Clinical Investigation
Subjects:
Ophthalmology
Therapeutics
Online Access:https://doi.org/10.1172/JCI163290

Internet

https://doi.org/10.1172/JCI163290

Similar Items